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ABSTRACT
The effects and modes of action of certain antineoplastic phospholipid
analogues (racemic l-O-octadecyl-2-O-methyl glycero-3-phosphocho-
line, BM 41.440, JH-1, CV-3988, and HePC) on (sodium plus potas-
sium)-activated adenosine triphosphatase (Na,K-ATPase) and sodium
pump activities were investigated. Inhibition of Na,K-ATPase in purified
rat brain synaptosomal membranes by these lipids, in contrast to ouabain,
was subject to membrane surface dilution and unaffected by whether the
reaction was started with Ml. NaCI, or ATP. Kinetic analysis indicated
that the analogues, again dissimilar to ouabain, were likely to interact
directly or indirectly with sodium-binding sites of Na,K-ATPase located
at the intracellular surface of the plasma membrane, a conclusion also
supported by studies using the inside-out vesicles of human erythrocyte
membranes. The studies also showed that ouabain (but not the lipids)
increased the affinity constant of Na.K-ATPase for K*, whereas the lipids
(but not ouabain) increased that for Na*. The lipids also inhibited ""Kb
uptake by intact human leukemia HL60 cells at potencies quite com
parable to those seen for inhibition of purified protein kinase C or Na.K-
ATPase. It is suggested that Na,K-ATPase (sodium pump) might repre
sent a hitherto unrecognized site of action for the lipid analogues, and
that the antineoplastic effects of the agents might be due to, in part,
inhibition of both protein kinase C and Na,K-ATPase and perhaps other
membrane-associated enzymes.
INTRODUCTION
Ether phospholipids and derivatives, as experimental anti-
cancer agents, have become a focus of research in recent years(for reviews, see Refs. 1 and 2). For example, ET-18-OCH.,,4
the prototype of the alkyllysophospholipid class of agents (3),
has been shown to inhibit growth (3, 4) and metastasis (5) of
syngeneic murine tumors and the growth of some rat tumors
(6) and human leukemic HL60 cells in culture (7, 8). Several
modes or mechanisms of action have been postulated to account
for its biological effects. These include enhancement of cyto-
toxic properties of macrophages (3-5), alterations of phospho
lipid metabolism (9), and inhibition of PKC (10). We reported
previously that, besides ET-18-OCH, (10), the antineoplastic
lipoidal amine CP-46,665-1 (11) and the thioether analogue of
phospholipid BM 41.440 (12), as well as the clinically useful
anticancer drugs Adriamycin (13) and tamoxifen (14), inhibited
PKC at potencies comparable to those for in vitro inhibition of
growth of cancer cells (see Refs. 1, 2, and 10 to 14 and papers
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cited therein). These findings suggested that PKC might rep
resent a potential site of action of the lipid agents and certain
anticancer drugs.
Na,K-ATPase, like PKC, is a major membrane enzyme play
ing a pivotal role in cell function. Because Na,K-ATPase is also
regulated by lipids (15), we suspected that certain lipid ana
logues shown to be PKC inhibitions would also inhibited Na,K-
ATPase. We found in the present studies that ET-18-OCH.,,
BM 41.440, JH-1, CV-3988, and HePC inhibited purified PKC
and Na.K-ATPase as well as sodium pump in intact HL60 cells
with comparable potencies.
MATERIALS AND METHODS
Materials. PS (bovine brain), ouabain, and histone HI (type III-S)
were purchased from Sigma Chemical Co. (St. Louis, MO); ET-18-
OCHj was from Medmark Chemicals (Muenchen-Gruenwald, Federal
Republic of Germany); BM 41.440 was from Boehringer Mannheim
(Mannheim, Federal Republic of Germany); and CV-3988 was from
Takeda Chemical Industry (Osaka, Japan). JH-1 (16) and HePC (17)
were synthesized and provided by the corresponding authors.
Preparations of Na,K-ATPase and PKC. Na,K-ATPase was purified
from rat cerebral cortex synaptosomes by extraction with sodium
dodecyl sulfate and discontinuous sucrose density centrifugation, ac
cording to the procedure of Matsuda and Cooper (18) modified from
the original method of Jorgensen (19). Mg2+-dependent ATPase activity
in this enzyme preparation was less than 3% of the total ATPase
activity. PKC was purified from pig brain extracts through the phenyl-
Sepharose affinity step (20); the enzyme preparation was devoid of
other contaminating protein kinase activities.
Assays for Enzymes. Na.K-ATPase activity was assayed as described
(21). Briefly, the standard reaction mixture (0.5 ml) consisted of 3 mivi[â€¢y-12P]ATP(containing about 2 to 8 x IO6cpm), 4 mM MgCl2, 20 mM
KC1, 100 mM NaCI, 1 mM EDTA, 50 HIM Tris/HCI (pH 7.4), and
appropriate amounts of the enzyme (membrane) preparation. The re
action, started by the addition of either ["y-32P]ATP,KC1, or NaCI and
carried out for 15 min at 37Â°C,was terminated by the addition of 1 ml
of ice-cold 5% (w/v) charcoal (Norite SG Extra; Baker) suspended in
0.1 M HC1, 1 miviNaH2PO4, and 1 mM NajPiO,, and the "P released
was determined as described (22). Na-ATPase activity in the Na,K-
ATPase preparations was assayed as described (23) except that the
concentration of MgCl2 was increased to 4 mM. Briefly, the standard
reaction mixture (0.5 ml) consisted of 1 Ã•IM[7-"P]ATP (containing
about 5 x IO6 cpm), 4 mM MgCl2, 100 mM NaCI, 1 mM EDTA, 50
mM Tris/HCI (pH 7.4), and appropriate amounts of the membrane
preparation. The reaction was started with [^-"PjATP and carried out
for 15 s at 37Â°C;the 12Prelease was determined as described above for
Na.K-ATPase. The activity of K-NPPase was assayed by measuring the
absorbance at 410 nm of p-nitrophenol released as described (21). The
standard reaction mixture (0.5 ml) consisted of 3 mM NPP, 4 mM
MgCl2, 20 mM KCI. 1 mM EDTA, 50 mM Tris/HCI (pH 7.4), and
appropriate amounts of the membrane preparation. The reaction,
started with NPP, was carried out for 15 min at 37Â°C.PKC was assayed
as described elsewhere (24). Briefly, the standard reaction mixtures (0.2
ml) contained 5 Mmol of Tris/HCI (pH 7.5), 2 umo\ of MgCl,, 0.8 ug
of protein of rat synaptosomal membrane (substituting 2 ^g of PS), 40
p%of histone HI, either 0.8 nmo\ of ethylenegiycol bis(ÃŸ-aminoethyl
3025
INHIBITION OF PKC. Na.K-ATPase, AND SODIUM PUMP BY PHOSPHOLIPID ANALOGUES
ether)-A'rAr,A",A'-tetraacetic acid or 0.04 Â¿imolof CaClj, 1 nmol of [7-
"P]ATP (containing about l x IO6cpm), and appropriate amounts of
enzyme. The reaction, started with [7-"P)ATP, was carried out for 5
min at 30Â°C.The activities of all enzymes studied were linear as a
function of incubation time or enzyme amount under the experimental
conditions. All experiments concerning the effects of the agents on the
enzymes as well as other experiments using membrane vesicles and
HL60 cells (see below) were repeated 2 to 4 times to ascertain repro-
ducibility of the findings reported herein.
Inside-out Membrane Vesicles of Erythrocytes. Vesicles were pre
pared from fresh human red blood cells according to the procedure of
Blostein and Chu (25). The resulting vesicles were 80 to 85% inside-
out as judged by the ratio of acetylcholinesterase activity in the presence
or absence of Triton X-IOO (26). The ATPase activity of the vesicles
was assayed by the method of Cariili et al. (27). Briefly, vesicles were
loaded by overnight equilibration at 0Â°Cin loading medium (20 mvi
Tris/glycylglycine, pH 7.4, containing 1 mM MgCl?, 10 ITIMNaCI, and
5 miviKC1). The reaction mixture (0.1 ml) consisted of 10 mM NaCI, 5
mM KC1, 1 mM MgCl2, 1 mM [^-"PjATP (containing about 5 x 10"
cpm), and appropriate amounts of vesicles in the presence of 1 MM
valinomycin, 20 mM Tris/glycylglycine (pH 7.4), and 0.5 ng of monen-
sin (to dissipate ion gradients) and 100 /Â¿Mouabain (to inhibit Na.K-
ATPase in unsealed vesicles).
"Rb Uptake by HL60 Cells. Cultured human leukemic cells, from
the mid-log growth phase, were used for 86Rbuptake studies, essentially
according to the procedures of Chopra and Gupta (28) described for
HeLa cells and detailed in the legend to Fig. 8.
Treatment of Agents. Ouabain and all lipid analogues, dissolved in
water, and strophantidin, in dimethyl sulfoxide, were diluted to appro
priate concentrations with 25 mM Tris/HCl (pH 7.4). Aliquots of these
agents were added directly to incubation mixtures containing the en
zyme or vesicle preparations or cells, as indicated in individual experi
ments.
Other Methods. [7-32P]ATP was prepared by the method of Post and
Sen (29). Protein was determined according to the procedure of Lowry
et al. (30), using bovine serum albumin as the standard.
RESULTS
The structures of representative synthetic phospholipid ana
logues used in the present studies are shown (Fig. 1). With the
exception of HePC (hexadecyl phosphocholine), all other ana
logues (ET-18-OCH,, BM 41.440, JH-1, and CV-3988) are
derivatives of glycerol phospholipids.
Inhibition studies of PKC by the lipid analogues were carried
out using a purified preparation of rat synaptosomal mem
branes (4 fig of protein/ml, or 5.5 Â¡igof PS equivalents/ml) as
the source of the phospholipid cofactor, instead of PS vesicles
(4 to 10 Mg/ml) under the standard assay conditions reported
elsewhere (10-14, 24). The same concentration of membranes
used in the above PKC studies was used as the source of purified
























Fig. l. Structures of some synthetic phospholipid analogues.
that the inhibition potencies of the analogues of both enzymes
could be compared directly. The IC50 values of the membrane-
activated PKC for JH-l, CV-3988, ET-18-OCH.,, BM 41.440,
and HePC were found to be 5, 5, 8, 9, and 9 pM, respectively
(data not shown). The values for PS-activated PKC under the
standard assay condition have been previously reported to be
lOyuMfor ET-18-OCH, (10) and 15/iM for BM 41.440 (12).
Because both PKC and Na,K-ATPase are membrane bound
and require phospholipids for their activation, we examined if
the lipid PKC inhibitors could also regulate Na.K-ATPase and
sodium pump compared with ouabain, the classic inhibitor.
Na.K-ATPase in purified rat brain membranes was inhibited by
JH-1, CV-3988, and HePC, and this inhibition was attenuated
by increasing amounts of the membrane preparation (Fig. 2, B
to D). Thus the IC5<>values for JH-1, for example, were 9, 20,
and 40 MMat membrane protein concentrations of 2, 4, and 8
Aig/ml, respectively, consistent with the notion that the lipids
are membrane interacting and subject to membrane surface
dilution. The inhibitory potency of ouabain (non-lipid glyco-
side), in comparison, was unaffected by the membrane concen

































120 T D HePC
100
O VA-1
O 1 10 100
AGENT
O 1 100
Fig. 2. Effects of ouabain. JH-1, CV-3988. and HePC on Na.K-ATPase in
purified rat synaptosomal membranes as a function of the enzyme amount. The
enzyme preparation (2, 4. or 8 Â¿igof protein/ml) was preincubated for 30 min
with various kinds and concentrations of the agents, as indicated. The reaction
was started by the addition of KCI. and the incubation times were 30, 15, and 7.5
min. respectively, for the above-indicated enzyme amounts. The standard reaction
mixture contained 100 mM NaCI. 20 HIMKCI. 4 mM MgCI2. I mM EDTA. and
3 mM ATP. The activity values obtained in the absence of added agents (8.7 Â±
0.4 UMof phosphate released/min/mg of protein) were taken as 100%. Points.
mean of triplicate incubations with assay errors being less than 4c/c.See "Materials
and Methods" for further details.
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trations when the reaction was started with KCl (Fig. 2A). For
the reason of simplicity and consistency, a fixed membrane
concentration (4 ng of protein/ml) was used in subsequent
experiments (Figs. 3 to 6).
In order to explore the mode of inhibition by the lipid
metabolites on Na,K-ATPase, we examined their actions under
various incubation conditions. Ouabain was more potent in
inhibiting the enzyme when the reaction was started with KCl
(IC50 of about 0.1 MM)than when NaCl or ATP (IC50 of about
l Â¿Â¿Mfor both) was used to initiate the reactions (data not
shown). It has been reported previously that K* reduced the
association and dissociation rate constants for the cardiac gly-
coside-ATPase interactions (31), suggesting that ouabain acted
primarily on K+-binding sites located at the extracellular side
of plasma membrane. JH-1, CV-3988, and HePC, in compari
son, inhibited Na,K-ATPase with similar potencies whether the
reaction was started with KCl, NaCl, or ATP (data not shown).
We have observed similar phenomena for the other lipid ana
logues ET-18-OCH., and BM 41.440 (32). It appears that there
is no strict structural requirement for Na,K-ATPase inhibition
by lipid substances, consistent with the nonspecificity in the
lipid requirement of Ca-ATPase or Na,K-ATPase activity (15).
The IC50 values for the agents of PKC and Na,K-ATPase
from experiments shown above and of 86Rb uptake by HL60
cells (see Fig. 8) are summarized (Table 1) for comparison.
The effects of the agents on the two partial reactions of Na,K-
ATPase, i.e., Na-ATPase and K-NPPase, were also examined
(data not shown). The reactions were started with the addition
of their respective substrates. Na-ATPase, stimulated by Na+
alone in the presence of low (micromolar) concentrations of
ATP, is thought to represent the phosphorylation step (El
stage) (33), whereas K-NPPase represents the dephosphoryla-
tion step (E2 stage) (34) of the Na.K-ATPase reaction. Ouabain
inhibited Na-ATPase with a potency similar to its inhibition of
Na,K-ATPase and an IC50 of about 2 ^M. In comparison,
ouabain was much less effective in inhibiting K-NPPase with
an ICjo of about 100 UM;this was due to a slow and incomplete
binding of the glycoside to Na.K-ATPase in the absence of Na+
and in the presence of K+, conditions optimal for K-NPPase
activity. All lipid analogues tested (JH-1, CV-3988, BM 41.440,
ET-18-OCH,, and HePC) had IC50values of about 20 to 30 ^M
for the two partial reactions (data not shown), values com
parable to those seen for Na.K-ATPase shown in Fig. 2 above.
Kinetic analysis of Na.K-ATPase inhibition by the analogues
Table 1 Summary of ICsa values for ouabain and lipid substances of PKC and
Na,K-ATPase activities and MKb uptake by HL60 cells
The values were taken from the present or previous studies. Synaptosomal
membranes (4 ^g of protein/ml or 5.5 ng of PS equivalents/ml) were used in the
PKC assay as the source of phospholipid cofactor and in the Na.K-ATPase assay





Â°Corrected for the ouabain-insensitive species, which accounted for 20% of
total uptake activity.
* Estimated from Fig. 8.
'Taken from Ref. 32.
d Taken from Ref. 39.
as a function of KCl concentration revealed that ouabain inhib
ited the enzyme competitively, whereas JH-1, CV-3988, and
HePC noncompetitively, with respect to K* (Fig. 3). Skou (36)
reported previously the same inhibitory kinetics for ouabain. It
is worth noting that a mixed competitive and noncompetitive
inhibition was also observed at high (micromolar) concentra
tions of ouabain (data not shown), suggesting that a hetero-
trophic, allosteric interaction existed between the glycoside
binding and K+ activation (37). The degrees of cooperativity
and KM for K+ were analyzed using Hill plots (Fig. 4), based
upon the data shown in Fig. 3 or similar experiments (data not
shown). Similar degrees of cooperativity (Hill coefficients of
about 1.2 to 1.9) for K+were observed in the absence or presence
of any of the agents and, furthermore, only ouabain (but not
JH-1, CV-3988, and HePC) increased the AT0.5value (for ex
ample, from 1.1 to 4.3 ^M at 0.4 /Â¿Mouabain). Kinetic analysis
of inhibition by the agents as a function of NaCl concentration
(Fig. 5) and Hill plots of the data (Fig. 6) are also presented. It
was found that ouabain inhibited the enzyme noncompetitively,
whereas the lipid analogues inhibited it competitively with
respect to Na*. Hill plots indicated that, while none of the
agents affected the degree of cooperativity (Hill coefficients of
about 1.0 to 1.3), JH-1, CV-3988, and HePC (but not ouabain)
increased the K0.svalue for Na+ (for example, from 8.0 to 20.9
/Â¿Mat 12 /UMJH-1). These results suggested that the lipid
analogues inhibited Na,K-ATPase by directly or indirectly in
teracting with the Na+-binding sites, whereas ouabain inhibition
was likely in part due to its interactions with K+-binding sites.
Previous studies on the sodium pump indicated that there
are multiple Na+-binding sites at both intra- and extracellular
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Fig. 3. Lineweaver-Burk plots showing inhibition by ouabain. JH-1, CV-3988.
and HePC of K*-dependent activation of synaptosomal membrane Na.K-ATPase.
The reaction, started with ATP. was carried out under the standard condition
(containing 100 mM NaCl) except for the varying concentrations of KCl ( I to 50
m\i) and the inhibitors, as indicated. The activity values presented were corrected
for the basal activity (0.3 M\' of phosphate/min/mg of protein) seen in the absence
of added KCl. Points, mean of triplicate incubations with assay errors being less
than 4%.
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Fig. 4. Hill plots showing the effects of ouabain, JH-1, CV-3988, and HePC
on K*-dependent activation of synaptosomal membrane Na,K-ATPase. The plots
were based upon the data shown in Fig. 3 covering 1 to 50 mM KCI. i', observed
reaction rate; Vm, maximal reaction rate (unit = /IM of phosphate/min/mg of
protein).
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Fig. 5. Lineweaver-Burk plots showing inhibition by ouabain. JH-1, CV-3988,
and HePC of Na*-dependent activation of synaptosomal membrane Na.K-
ATPase. The reaction, started with ATP. was carried out under the standard
condition (containing 20 mM KCI) except for varying concentrations of NaCI (3
to 100 mM) and the inhibitors, as indicated. The activity values presented were
corrected for the basal activity (3.5 JIM of phosphate/min/mg of protein) seen in
the absence of added NaCI. Points, mean of triplicate incubations with assay
errors being less than 5%.
faces of the plasma membrane (38). Although the present
kinetic studies, using the purified membrane fragments, sug
gested that the lipid analogues competed with Na+-binding sites
on Na,K-ATPase, it is unclear where the lipids interacted. In
order to further explore the problem, we used inside-out vesicles
of erythrocyte membranes for the next series of experiments.
In these experiments, Na,K-ATPase activity of the vesicles was
defined as the ATPase activity that was resistant to ouabain
(membrane-impermeable inhibitor) but was sensitive to stro-
O.e 1.0 1.4 0.6 1.0 1.4 0.6 1.0 1.4 0.6 1.0 1.4
Fig. 6. Hill plots showing the effects of ouabain, JH-1, CV-3988. and HePC
on Na*-dependent activation of Na.K-ATPase. The plots were based upon the
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Fig. 7. Effects of JH-1. CV-3988. BM 41.440, and ET-18-OCHj on ATPase
activities in inside-out vesicles(/OF) of human erythrocytes. The vesicles(650 <*g
of protein/ml) were preincubated with or without 0.4 m.\i strophantidin for 30
min, followed by further preincubation with or without the agents for an additional
15 min, as indicated. The reaction was started with ATP and carried out for 10
min at 37"C. The difference in ATPase activity seen in the absence(total activity)
or presence (resistant activity) of strophantidin was taken as the strophantidin-
sensitive Na.K-ATPase activity. Columns, mean of triplicate incubations, ex
pressed as the percentage of the respective control values seen in the absence of
the agents: bars, SE. The control values for strophantidin-sensitive and -resistant
ATPase activities were 0.73 and 1.60 Â¿/Mof phosphate/min/mg of protein,
respectively. See "Materials and Methods" for further details. .9, strophantidin.
phantidin (membrane-permeable inhibitor) (27). JH-1, CV-
3988, BM 41.440, and ET-18-OCHj showed a dose-dependent
inhibition of strophantidin-sensitive activity, with IC5Uvalues
estimated to be about 100 to 200 n\i (Fig. 7). The requirement
of high concentrations of the lipids to inhibit the vesicular
Na,K-ATPase was probably due to surface dilution, because a
high amount of membrane (650 ^g of protein/ml) was required
for the assay. The strophantidin-resistant activity, in compari
son, was not inhibited by the lipid analogues (Fig. 7). Similar
findings were also made for lyso-PC and sphingosine (39).
Finally, human leukemia HL60 cells were used to investigate
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Fig. 8. Effects of ouabain and phospholipid analogues on 8*Rb uptake by
HL60 cells. The cells (7 x I05/0.5 ml/tube), in RPMI-1640 medium containing
10% fetal calf serum, were preincubated at 37"C for 3 h with ET-18-OCH, and
0.5 h with other analogues. The cells were not preincubated with ouabain. To
each tube Â»asthen added "Rb (I /Â¿Ci),and the uptake was carried out for 0.5 h.
The reaction was stopped by the addition of 1 ml of ice-cold washing buffer (25
HIMTris/HCI. pH 7.4. containing 145 mM choline chloride. 0.8 mM MgSO4. and
1.8 mM CaCli). and the cells were washed 3 times with 1 ml of the same buffer.
The cell pellets were finally dissolved in 0.25 ml of 0.5% deoxycholic acid in 0.1
N NaOH. and the 86Rb taken up by the cells was determined using a gamma
counter. Points, mean of triplicate determinations; the control activity value seen
in the absence of added agents (151.3 Â±12.0 pmol of "Rb uptake/7 x 10' cells/
h) was taken as \OOTc.The cell viability (as determined by trypan blue exclusion)
in all treatments shown was >96%. Higher concentrations of the lipid agents
caused extensive cell lysis and. therefore, could not be used for the studies.
the effects of the lipid analogues on the sodium pump in intact
cells using 86Rb uptake as an indicator of the pump activity.
Ouabain at concentrations as high as 1000 MMinhibited the
uptake by about 80%, indicating that only about 20% of the
pump activity in HL60 cells was ouabain resistant. Preincuba-
tion of the cells for 0.5 or 3 h with varying concentrations of
the lipid analogues resulted in a dose-dependent inhibition of
the uptake (Fig. 8). Their IC50 values, estimated to be 9 to 40
/IM, are also summarized (Table 1). The IC5o for ET-18-OCH.,
(3-h incubation) was 9 ^M, whereas the values for others (0.5-h
incubation) were 25 to 40 /UM,which could be lower if the cells
were pretreated with the agents for a longer time (e.g., 3 h).
The notion was supported in part by our findings that the IC50
for ET-18-OCH., was about 30 ^M if the preincubation time
was only 20 min.5
DISCUSSION
Negatively charged boundary phospholipids (such as PS),
located at the inner membrane, have been suggested to act as
endogenous activators of Na,K-ATPase or the sodium pump
(15). Modification of the membrane lipid composition would
therefore probably lead to changes in membrane properties and
function. We observed in the present studies that several phos
pholipid analogues inhibited Na,K-ATPase of brain synapto-
somal membranes, and inside-out vesicles from erythrocyte
membranes, and 86Rb uptake (sodium pump) into intact HL60
cells. We also observed that these lipid analogues, in contrast
to ouabain, inhibited purified Na,K-ATPase competitively with
respect to Na+ and noncompetitively with respect to K+, and
that the inhibition was attenuated by increasing amounts of
membranes. These findings suggest that the lipid analogues
most likely interact with boundary phospholipid in the inner
s B. Zheng and J. F. Kuo. unpublished observations.
membrane and, as a consequence, result in increased local
fluidity and/or decreased interaction of acidic boundary phos
pholipids with Na,K-ATPase. Because ET-18-OCH, inhibited
the phorbol ester-induced protein phosphorylation and differ
entiation of HL60 cells (40), coupled with the well-recognized
fact that PS is the most effective phospholipid cofactor for
PKC, it is likely that the in vivo actions of ET-18-OCH, and
other lipid analogues might be mediated via similar membrane
effects leading to PKC inhibition. Although the lipid analogues
inhibited Na,K-ATPase in synaptosomal membranes and 86Rb
uptake into HL60 cells with comparable potencies, higher
concentrations of the analogues were required to inhibit Na.K-
ATPase in the inside-out vesicles of erythrocyte membranes.
This discrepancy might have been due to the unnatural (i.e.,
inside-out) state of the membranes of the blood cells, resulting
in an exceedingly high membrane surface dilution for the lipid
analogues.
Based upon studies on various compounds, Espan (41) has
concluded that agents (positively charged, uncharged, or zwit-
terionic) that stabilize the bilayer phase of membranes are
inhibitors, whereas agents (negatively charged, uncharged, or
zwitterionic) that destabilize the bilayer phase by promoting its
conversion to the hexagonal phase are activators of PKC. This
generalization, although useful as a model, appears too sim
plistic. The criteria for modifications of physical and functional
properties of the membrane as they are related to activation or
inhibition of PKC (or Na.K-ATPase) appear more complex.
This notion is supported, for example, by our recent studies
that a distearoylphosphatidylcholine derivative that is methyl
ated at position 8 of the fatty acyl group at position sn-2 of
glycerol is a potent inhibitor, but the corresponding butylated
analogue is a potent activator of PKC (42). The lipid analogues
used in the present studies (see Fig. 1 for structures) and the
distearoylphosphatidylcholine derivatives are all zwitterionic.
It is of interest to know how the positive or negative charge, or
both, of the agents could influence the membrane bilayer sta
bility, leading to altered hydrophobic interactions between the
enzyme protein and the membrane lipid, the events which are
presumably essential for inhibition/activation of PKC or Na.K-
ATPase.
We also observed in the present studies that the lipid ana
logues similarly inhibited purified PKC and Na,K-ATPase and
86Rb uptake (sodium pump) in intact HL60 cells (for summary,
see Table 1). It is conceivable, therefore, that the reported
antineoplastic (1-8) and antidifferentiation effects (40) of these
agents might be due to, in part, inhibition of both PKC and
Na.K-ATPase, and that such a combination of inhibitions could
produce a synergistic biological effect. However, PKC probably
was not involved in the sodium pump activity, because phorbol
esters, known to activate and down-regulate PKC in HL60 cells
(12), had no effect on 86Rb uptake by the cells (39).
It should be noted that HePC has a structure different from
the glycerol phospholipid class of the agents such as ET-18-
OCH, (see Fig. 1 for structures), representing a new class of
antineoplastic agents (43-46). HePC was found to be as effec
tive as glycerol lipids in inhibiting PKC, Na.K-ATPase, and
86Rb uptake in the present studies. It is likely that HePC,
lacking the glycerol backbone, has the minimal structural re
quirements essential for interacting with biomembranes, result
ing in inhibition of certain membrane enzymes and process
including selective tumor toxicity.
Lastly, we should probably attempt to understand the efficacy
of the lipid agents in terms of their mol % with respect to
membrane phospholipids. If one assumes that the average mo-
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10.
12.
lecular weight of phospholipids is 800 and that biomembranes REFERENCES
contain an equal amount of protein and phospholipids, then
the amount of synaptosomal membrane protein (0.8 ng in a
0.2-ml incubation volume) used in the present studies would
correspond to 0.8 ng, or 1.0 nmol, of total phospholipid. From
the data given in Table 1, for example, the IC50 for ET-18-
OCH.i for PKC inhibition was 9 //M (in a 0.2-ml incubation
volume), corresponding to 1.8 nmol of the agent. If one also
assumes that 50% of the agent was actually incorporated into
the membrane, then the molar ratio of the agent to total
phospholipid in the membrane would be 0.9 to 1.0 = 0.9, or 90
mol %. This value appears to be high (or the ether lipid to be
rather inactive), but a similar value (100 mol %) was also
obtained in separate experiments for sphingosine (39), the
putative endogenous PKC inhibitor (47). We have also noted
that diacylglycerol (such as diolein), the acknowledged second
messenger (48), half-maximally activated PKC at 2 /UMunder
the same assay conditions (39), corresponding to 20 mol % for
the activator. We reported previously that a half-maximal ac
tivation of PKC required 1 mol % of diolein in the mixed
micelle assay system of Hannum et al. (47), which consisted of
0.3% Triton X-100 and 6 mol % of PS, corresponding to 17
mol % of diolein with respect to PS (49). Based upon the IC50
(16 MM)of Na,K-ATPase for ET-18-OCH., shown in Table 1
and the assumptions used in synaptosomal membranes, it was
calculated that 160 mol % of the agent were required to inhibit
the enzyme activity by 50%. Similarly, from the 1C,,, value
(about 120 MM.in 0.1-ml incubation volume) for ET-18-OCH,
of strophantidin-sensitive Na,K-ATPase in erythrocyte inside-
out vesicles (65 pg of protein/0.1 ml) (Fig. 7). the value for the
agent was calculated to be 7 mol %.
It was of interest to carry out similar calculations with the
inhibition of S6Rb uptake (sodium pump) in intact HL60 cells.
We assumed that the number of cells (7 x IO5) used in Fig. 8
would correspond to 5 mg of total cellular proteins or 1 mg
(1250 nmol) of the membrane phospholipid. The IC50 of ET-
18-OCH, was 9 MM(in 0.5-ml incubation volume) (Table 1). If
only 10% of the agent (0.45 nmol) were actually taken up into
cell membrane (90% remained bound to serum in the medium),
then the ratio of the agent to total membrane phospholipid
would be 0.45 to 1250 = 0.00036, or 0.036 mol %, a value
clearly below the one that could cause cell lysis by lysophos-
pholipids. Because the IC50values for ET-18-OCH, of phorbol
ester-stimulated endogenous protein phosphorylation and dif
ferentiation of HL60 cells (40) were similar to those seen for
86Rb uptake (Fig. 8), it was concluded that the effects of the
agent and its structural analogues on the intact cells were
specific and were not due to a general phenomenon of mem
brane perturbation brought about by the lipids. The reasons for
the requirement of about three orders of magnitude higher mol
% of ET-18-OCH, to inhibit PKC or Na.K-ATPase using
synaptosomal membrane fragments than to inhibit cellular
activities in intact HL60 cells are unclear. It is plausible that
the effects of the lipid agents on intact cells (such as cytotox-
icity, inhibition of the sodium pump, and leukemia cell differ
entiation) are the combined results of their actions on the
individual targets (such as PKC, Na,K-ATPase, and phospho-
lipid-metabolizing enzymes), perhaps acting synergistically.
The isolated membrane preparations (or PS vesicles), however,
are still useful as a model in studies aiming to illustrate the
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